Generic name
Temazepam: adverse event reports filed with FDA
7,422 reports list it as a suspect or interacting product, 2004–2026. Class: Benzodiazepine. Also reported as Temazepam Capsules, Temazepam Capsules Usp, Temazepam Capsules 15mg.
- 7,422
- reports as suspect product
- 0% of all reports · about 331 a year
- 308
- reports, 12 months to June 2026
- 487 in the 12 months before
- 90.7%
- marked serious by the reporter
- 88.1% across the class
- 52.6%
- record death among outcomes, as reported
- 3,906 reports · not verified by FDA
Between February 2004 and June 2026, 7,422 adverse event reports received by FDA list temazepam, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (23,302) are left out of every figure here.
In the 12 months to June 2026, 308 reports listed it, down 37% from 487 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 331 reports a year and 0% of the 20,646,523 reports in the database, and 3% of the reports for the benzodiazepine class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are toxicity to various agents (25.8%), completed suicide (16.9%) and overdose (12.1%). A report can list several reactions, so shares add to more than 100%; 993 different terms appear across these reports. Toxicity to various agents is recorded in 25.8% of these reports, a larger share than in the median benzodiazepine drug (6.2%).
90.7% of the reports are marked serious by the reporter (88.1% across the class); 52.6% record death among the outcomes and 19.8% record hospitalisation, as reported. 42.9% of the reports came from other health professionals, and the largest patient age group is 18 to 44 (30.8%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Temazepam reports recording the termmedian drug in benzodiazepine
- Toxicity to various agentspoisoning or toxic effect of one or more substances25.8%1,914
- Completed suicidedeath by suicide16.9%1,252
- Overdosea dose above the recommended amount12.1%896
- Drug abusemisuse of a medicine10.4%775
- Drug ineffectivethe medicine did not work as expected9.3%693
- Off label useused for a purpose or in a way not on the label7.6%564
- Headachehead pain6.8%503
- Painpain, site not specified6.8%501
- Deaththe patient died; cause not stated by this term6.7%497
- Hyperhidrosisexcessive sweating6.1%454
- Drug interactionan interaction between medicines6%442
- Hypersensitivityan allergic-type reaction5.8%429
- Exposure during pregnancythe medicine was taken during pregnancy5.6%417
- Product use issuea problem in how the product was used5.6%415
- Hepatic enzyme increasedraised liver enzymes5.5%405
- Intentional product misusedeliberate use not as intended5.4%401
- Fatiguetiredness5.3%393
- Asthmaasthma5.2%389
- Immunodeficiency5.2%387
- Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease5.1%382
- Food allergy5.1%379
- Hypertensionhigh blood pressure5%374
- Prescribed overdose4.7%351
- Upper respiratory tract infectiona cold or similar infection4.6%341
- Rash erythematousa red rash4.5%334
- Joint swellinga swollen joint4.4%325
- Infusion related reactiona reaction during or soon after an infusion4.3%319
- Somnolencedrowsiness4.1%308
- Back painback pain4.1%302
- Fluid retentionthe body holding extra fluid4%298
Top 30 of 993 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 19 drugs in the benzodiazepine class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 244,289 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 45.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Insomnia | 481 | 6.5% |
| Sleep disorder | 206 | 2.8% |
| Suicide attempt | 96 | 1.3% |
| Poor quality sleep | 58 | 0.8% |
| Anxiety | 42 | 0.6% |
| Drug abuse | 29 | 0.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 7,422 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Temazepam reports |
|---|---|---|
| Diazepam | 2,114 | 28.5% |
| Oxazepam | 1,437 | 19.4% |
| Gabapentin | 1,049 | 14.1% |
| Acetaminophen | 973 | 13.1% |
| Codeine | 961 | 12.9% |
| Zopiclone | 757 | 10.2% |
| Lorazepam | 647 | 8.7% |
| Alprazolam | 620 | 8.4% |
| Furosemide | 617 | 8.3% |
| Bupropion hydrochloride | 594 | 8% |
Other products listed in reports where Temazepam is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Temazepam | Benzodiazepine | All reports |
|---|---|---|---|
| Reports as suspect product | 7,422 | 244,289 | 20,646,523 |
| Share of that pool | — | 3% | 0% |
| Reports, latest 12 months | 308 | — | 1,332,454 |
| Marked serious | 90.7% | 88.1% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 526 | 297 | 91 |
| Hospitalisation recorded, per 1,000 reports | 198 | 346 | 213 |
| Consumer-filed share | 18.1% | 21.3% | 45.8% |
| Top term, share of reports | Toxicity to various agents 25.8% | median 6.2% | 0.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the benzodiazepine class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Alprazolam | generic | 48,263 | 2,271 | 90.4% |
| Diazepam | generic | 40,060 | 2,762 | 94.8% |
| Clonazepam | generic | 37,432 | 2,530 | 86.7% |
| Lorazepam | generic | 33,307 | 2,010 | 90% |
| Xanax | brand | 17,444 | 520 | 78.2% |
| Midazolam | generic | 11,299 | 872 | 92.6% |
| Oxazepam | generic | 10,709 | 1,200 | 99.1% |
| Valium | brand | 9,650 | 477 | 84% |
| Clobazam | generic | 8,005 | 712 | 89.1% |
| Klonopin | brand | 5,832 | 56 | 56.5% |
| Ativan | brand | 5,318 | 255 | 77.8% |
| Onfi | brand | 3,543 | 41 | 57.5% |
| Midazolam hydrochloride | generic | 1,731 | 125 | 88.6% |
| Triazolam | generic | 1,479 | 66 | 84.3% |
| Restoril | brand | 1,018 | 66 | 79.8% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Temazepam reports
How many adverse event reports has FDA received for Temazepam?
7,422 reports list Temazepam as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 308 of them arrived in the latest 12 months. Another 23,302 list it only as a concomitant medication.
What reactions are recorded in Temazepam reports?
toxicity to various agents (25.8%), completed suicide (16.9%), overdose (12.1%), drug abuse (10.4%) and drug ineffective (9.3%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Temazepam was responsible.
How serious are the reports?
90.7% are marked serious by the reporter. Among the outcomes recorded, 52.6% of reports include death and 19.8% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (42.9%), physician (26.1%) and consumer or non-health professional (18.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Temazepam rising?
308 reports in the 12 months to June 2026, down 37% from 487 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Temazepam was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Temazepam?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Temazepam as a suspect or interacting product; reports listing it only as a concomitant medication (23,302) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.